Management of high-risk HPV-positive women for detection of cervical (pre)cancer

Expert Review of Molecular Diagnostics

Volumn 16, Issue 9, 2016, Pages 961-974

  Luttmer, Roosmarijn ^a,b   De Strooper, Lise M A ^a   Steenbergen, Renske D M ^a   Berkhof, Johannes ^a   Snijders, Peter J F ^a   Heideman, Daniëlle A M ^a   Meijer, Chris J L M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b DEPARTMENT OF SURGERY   (Netherlands)

Author keywords

biomarker; cervical cancer; cervical intraepithelial neoplasia (CIN); cytology; DNA methylation; genotyping; Human papillomavirus; p16 Ki 67 dual stained cytology; screening; triage

Indexed keywords

BIOLOGICAL MARKER; DNA; DNA METHYLTRANSFERASE; KI 67 ANTIGEN; PROTEIN P16; VIRUS DNA; CYCLIN DEPENDENT KINASE INHIBITOR 2A;

ARTICLE; CANCER DIAGNOSIS; COLPOSCOPY; DNA METHYLATION; FEMALE; GENOTYPE; HIGH RISK PATIENT; HOST CELL; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; INFECTION RISK; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; EMERGENCY HEALTH SERVICE; GENETICS; GENOTYPING TECHNIQUE; METABOLISM; PAPILLOMAVIRUS INFECTIONS; PRECANCEROUS CONDITIONS; PROCEDURES; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; DNA, VIRAL; FEMALE; GENOTYPING TECHNIQUES; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; KI-67 ANTIGEN; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTIONS; PRECANCEROUS CONDITIONS; TRIAGE; UTERINE CERVICAL NEOPLASMS;

EID: 84982851430     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1080/14737159.2016.1217157     Document Type: Article

References (119)

1. J.Ferlay, I.Soerjomataram, R.Dikshit, et al. Cancer incidence and mortality worldwide:sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E386.
2. L.A.Torre, F.Bray, R.L.Siegel, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
3. H.Zur Hausen Papillomaviruses and cancer:from basic studies to clinical application. Nat Rev Cancer. 2002;2(5):342–350.
4. D.M.Harper, E.L.Franco, C.M.Wheeler, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18:follow-up from a randomised control trial. Lancet. 2006;367(9518):1247–1255.
5. J.Paavonen, P.Naud, J.Salmeron, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA):final analysis of a double-blind, randomised study in young women. Lancet. 2009;374(9686):301–314.
6. E.A.Joura, A.R.Giuliano, O.-E.Iversen, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711–723.
7. T.Malagón, V.Joumier, M.-C.Boily, et al. The impact of differential uptake of HPV vaccine by sexual risks on health inequalities:a model-based analysis. Vaccine. 2013;31(13):1740–1747.
8. M.A.Vink, J.A.Bogaards, F.J.van Kemenade, et al. Clinical progression of high-grade cervical intraepithelial neoplasia:estimating the time to preclinical cervical cancer from doubly censored national registry data. Am J Epidemiol. 2013;178(7):1161–1169.•• The natural history of transforming CIN and cervical cancer is described and provides an estimation of progression time to cervical cancer.
9. P.P.L.Martin-Hirsch, E.Paraskevaidis, A.Bryant, et al. Surgery for cervical intraepithelial neoplasia. Cochrane Database Syst Rev. 2013;12:CD001318.
10. J.Peto, C.Gilham, O.Fletcher, et al. The cervical cancer epidemic that screening has prevented in the UK. Lancet. 2004;364(9430):249–256.
11. S.Bulk, O.Visser, L.Rozendaal, et al. Incidence and survival rate of women with cervical cancer in the Greater Amsterdam area. Br J Cancer. 2003;89(5):834–839.
12. H.C.Kitchener, P.E.Castle, J.T.Cox. Chapter 7:achievements and limitations of cervical cytology screening. Vaccine. 2006;24(Suppl 3):S63–S70.
13. K.Nanda, D.C.McCrory, E.R.Myers, et al. Accuracy of the papanicolaou test in screening for and follow-up of cervical cytologic abnormalities:a systematic review. Ann Intern Med. 2000;132(10):810–819.
14. M.-H.Mayrand, E.Duarte-Franco, I.Rodrigues, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007;357(16):1579–1588.
15. H.C.Kitchener, M.Almonte, C.Thomson, et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC):a randomised controlled trial. Lancet Oncol. 2009;10(7):672–682.
16. D.C.Rijkaart, J.Berkhof, L.Rozendaal, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer:final results of the POBASCAM randomised controlled trial. Lancet Oncol. 2012;13(1):78–88.
17. P.Naucler, W.Ryd, S.Törnberg, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med. 2007;357(16):1589–1597.
18. M.Leinonen, P.Nieminen, L.Kotaniemi-Talonen, et al. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. J Natl Cancer Inst. 2009;101(23):1612–1623.
19. G.Ronco, P.Giorgi-Rossi, F.Carozzi, et al. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst. 2008;100(7):492–501.
20. G.Ronco, P.Giorgi-Rossi, F.Carozzi, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia:a randomised controlled trial. Lancet Oncol. 2010;11(3):249–257.
21. N.Bulkmans, J.Berkhof, L.Rozendaal, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer:5-year follow-up of a randomised controlled implementation trial. Lancet. 2007;370(9601):1764–1772.
22. N.W.J.Bulkmans, L.Rozendaal, F.J.Voorhorst, et al. Long-term protective effect of high-risk human papillomavirus testing in population-based cervical screening. Br J Cancer. 2005;92(9):1800–1802.
23. K.M.Elfstrom, V.Smelov, A.L.Johansson, et al. Long term duration of protective effect for HPV negative women:follow-up of primary HPV screening randomised controlled trial. Bmj. 2014;348:130.
24. G.Ronco, J.Dillner, K.M.Elfström, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer:follow-up of four European randomised controlled trials. Lancet. 2014;383(9916):524–532.•• This paper provides a pooled analysis indicating that primary HPV testing provides a better detection against cervical cancer compared with cytology testing.
25. M.Arbyn, G.Ronco, A.Anttila, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine. 2012;30(Suppl 5):F88–F99.
26. M.Arbyn, G.Ronco, C.J.L.M.Meijer, et al. Trials comparing cytology with human papillomavirus screening. Lancet Oncol. 2009;10(10):935–936.
27. M.Poljak, J.Cuzick, B.J.Kocjan, et al. Nucleic acid tests for the detection of alpha human papillomaviruses. Vaccine. 2012;30(Suppl 5):F100–F106.
28. N.van der Veen, M.E.M.Carpay, J.A.van Delden, et al. Uitvoeringstoets wijziging bevolkingsonderzoek baarmoederhalskanker. 2013.
29. Commonwealth of Australia. National Cervical Screening Program renewal:executive summary. 2013.
30. D.Saslow, D.Solomon, H.W.Lawson, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012;62(3):147–172.
31. J.Doorbar, N.Egawa, H.Griffin, et al. Human papillomavirus molecular biology and disease association. Rev Med Virol. 2015;25(Suppl 1):2–23.
32. R.D.M.Steenbergen, P.J.F.Snijders, D.A.M.Heideman, et al. Clinical implications of (epi)genetic changes in HPV-induced cervical precancerous lesions. Nat Rev Cancer. 2014;14(6):395–405.•• This paper provides an overview of new genetic and epigenetic molecular tools that might be used in cervical screening, diagnostics, and management of lesions.
33. S.M.Wilting, R.D.M.Steenbergen. Molecular events leading to HPV-induced high grade neoplasia. Papillomavirus Res. 2016;2:85–88.
34. A.G.Östör. Natural history of cervical intraepithelial neoplasia:a critical review. Int J Gynecol Pathol. 1993;12(2):186–192.
35. M.R.McCredie, K.J.Sharples, C.Paul, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3:a retrospective cohort study. Lancet Oncol. 2008;9(5):425–434.
36. F.J.Bruinsma, M.A.Quinn. The risk of preterm birth following treatment for precancerous changes in the cervix:a systematic review and meta-analysis. BJOG. 2011;118(9):1031–1041.
37. S.N.Conner, H.A.Frey, A.G.Cahill, et al. Loop electrosurgical excision procedure and risk of preterm birth:a systematic review and meta-analysis. Obstet Gynecol. 2014;123(4):752–761.
38. P.E.Castle, M.Sideri, J.Jeronimo, et al. Risk assessment to guide the prevention of cervical cancer. Am J Obstet Gynecol. 2007;197(4):356.e1–356.e6.
39. D.C.Rijkaart, J.Berkhof, F.J.van Kemenade, et al. Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. Int J Cancer. 2012;130(3):602–610.
40. M.G.Dijkstra, D.Van Niekerk, D.C.Rijkaart, et al. Primary hrHPV DNA testing in cervical cancer screening:how to manage screen-positive women? a POBASCAM trial substudy. Cancer Epidemiol Biomarkers Prev. 2014;23(1):55–63.
41. D.C.Rijkaart, J.Berkhof, F.J.van Kemenade, et al. HPV DNA testing in population-based cervical screening (VUSA-Screen study):results and implications. Br J Cancer. 2012;106(5):975–981.
42. M.S.Pepe, Z.Feng, H.Janes, et al. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction:standards for study design. J Natl Cancer Inst. 2008;100(20):1432–1438.
43. M.S.Pepe, R.Etzioni, Z.Feng, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst. 2001;93(14):1054–1061.
44. N.Wentzensen, J.Walker, M.Schiffman, et al. Heterogeneity of high-grade cervical intraepithelial neoplasia related to HPV16:implications for natural history and management. Int J Cancer. 2013;132(1):148–154.• This paper provides insight in the pathological heterogeneity of high-grade CIN lesions.
45. N.Wentzensen, M.Schiffman, T.Palmer, et al. Triage of HPV positive women in cervical cancer screening. J Clin Virol. 2016;76(Suppl 1):S49–S55.
46. K.Louvanto, M.Chevarie-Davis, A.V.Ramanakumar, et al. HPV testing with cytology triage for cervical cancer screening in routine practice. Am J Obstet Gynecol. 2014;210(5):474.e1–474.e7.
47. P.E.Castle, M.H.Stoler, T.C.J.T.L.Wright, et al. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older:a subanalysis of the ATHENA study. Lancet Oncol. 2011;12(9):880–890.
48. C.Bergeron, P.Giorgi-Rossi, F.Cas, et al. Informed cytology for triaging HPV-positive women:substudy nested in the NTCC randomized controlled trial. J Natl Cancer Inst. 2015;107:dju423. doi:10.1093/jnci/dju423.
49. A.T.Moriarty, R.Nayar, T.Arnold, et al. The Tahoe Study:bias in the interpretation of Papanicolaou test results when human papillomavirus status is known. Arch Pathol Lab Med. 2014;138(9):1182–1185.
50. L.A.Richardson, M.El-Zein, A.V.Ramanakumar, et al. HPV DNA testing with cytology triage in cervical cancer screening:influence of revealing HPV infection status. Cancer Cytopathol. 2015;123(12):745–754.
51. R.Luttmer, L.M.A.De Strooper, J.Berkhof, et al. Comparing the performance of FAM19A4 methylation analysis, cytology and HPV16/18 genotyping for the detection of cervical (pre)cancer in high-risk HPV-positive women of a gynecologic outpatient population (COMETH study). Int J Cancer. 2016;138(4):992–1002.
52. F.Garcia, B.Barker, C.Santos, et al. Cross-sectional study of patient- and physician-collected cervical cytology and human papillomavirus. Obstet Gynecol. 2003;102(2):266–272.
53. M.Budge, J.Halford, M.Haran, et al. Comparison of a self-administered tampon ThinPrep test with conventional pap smears for cervical cytology. Aust N Z J Obstet Gynaecol. 2005;45(3):215–219.
54. M.A.E.Nobbenhuis, T.J.M.Helmerhorst, A.J.C.van den Brule, et al. Primary screening for high risk HPV by home obtained cervicovaginal lavage is an alternative screening tool for unscreened women. J Clin Pathol. 2002;55(6):435–439.
55. A.A.T.P.Brink, C.J.L.M.Meijer, M.A.H.M.Wiegerinck, et al. High concordance of results of testing for human papillomavirus in cervicovaginal samples collected by two methods, with comparison of a novel self-sampling device to a conventional endocervical brush. J Clin Microbiol. 2006;44(7):2518–2523.
56. J.Cuzick, C.Clavel, K.-U.Petry, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006;119(5):1095–1101.
57. K.U.Petry, D.Schmidt, S.Scherbring, et al. Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 Dual-stained cytology. Gynecol Oncol. 2011;121(3):505–509.
58. D.Schmidt, C.Bergeron, K.J.Denton, et al. p16/ki-67 dual-stain cytology in the triage of ASCUS and LSIL papanicolaou cytology:results from the European equivocal or mildly abnormal Papanicolaou cytology study. Cancer Cytopathol. 2011;119(3):158–166.
59. N.Wentzensen, L.Schwartz, R.E.Zuna, et al. Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population. Clin Cancer Res. 2012;18(15):4154–4162.
60. H.Ikenberg, C.Bergeron, D.Schmidt, et al. Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology:results of the PALMS study. J Natl Cancer Inst. 2013;105(20):1550–1557.
61. M.Von Knebel Doeberitz. New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections. Eur J Cancer. 2002;38(17):2229–2242.
62. I.Tsoumpou, M.Arbyn, M.Kyrgiou, et al. p16INK4a immunostaining in cytological and histological specimens from the uterine cervix:a systematic review and meta-analysis. Cancer Treat Rev. 2009;35(3):210–220.
63. C.Bergeron, H.Ikenberg, M.Sideri, et al. Prospective evaluation of p16/Ki-67 dual-stained cytology for managing women with abnormal Papanicolaou cytology:PALMS study results. Cancer Cytopathol. 2015;123(6):373–381.
64. A.-J.Kruse, J.P.A.Baak, T.Helliesen, et al. Evaluation of MIB-1-positive cell clusters as a diagnostic marker for cervical intraepithelial neoplasia. Am J Surg Pathol. 2002;26(11):1501–1507.
65. N.Wentzensen, B.Fetterman, P.E.Castle, et al. p16/Ki-67 dual stain cytology for detection of cervical precancer in HPV-positive women. J Natl Cancer Inst. 2015;107(12):djv257.
66. INK4a –Ki-67 to define the management of human papillomavirus (HPV)–positive women in cervical cancer screening. Am J Clin Pathol. 2016;145(1):35–45.
67. R.Luttmer, M.G.Dijkstra, P.J.F.Snijders, et al. p16/Ki-67 dual-stained cytology for detecting cervical (pre)cancer in a HPV-positive gynecologic outpatient population. Mod Pathol. 2016;29(8):870–878. doi:10.1038/modpathol.2016.80
68. E.Allia, G.Ronco, A.Coccia, et al. Interpretation of p16(INK4a) /Ki-67 dual immunostaining for the triage of human papillomavirus-positive women by experts and nonexperts in cervical cytology. Cancer Cytopathol. 2015;123(4):212–218.
69. N.Wentzensen, B.Fetterman, D.Tokugawa, et al. Interobserver reproducibility and accuracy of p16/Ki-67 dual-stain cytology in cervical cancer screening. Cancer Cytopathol. 2014;122(12):914–920.
70. INK4a/Ki-67 double-staining in cytological screening of cervical cancer. Acta Cytol. 2011;55(5):413–420.
71. T.C.Wright, J.Compagno, P.Romano, et al. Amplification of the 3q chromosomal region as a specific marker in cervical cancer. Am J Obstet Gynecol. 2015;213(1):51.e1–51.e8.
72. R.Zappacosta, M.M.Ianieri, D.Buca, et al. Clinical role of the detection of human telomerase RNA component gene amplification by fluorescence in situ hybridization on liquid-based cervical samples:comparison with human papillomavirus-DNA testing and histopathology. Acta Cytol. 2015;59(4):345–354.
73. S.Andersson, P.Sowjanya, D.Wangsa, et al. Detection of genomic amplification of the human telomerase gene TERC, a potential marker for triage of women with HPV-positive, abnormal Pap smears. Am J Pathol. 2009;175(5):1831–1847.
74. K.Heselmeyer-Haddad, V.Janz, P.E.Castle, et al. Detection of genomic amplification of the human telomerase gene (TERC) in cytologic specimens as a genetic test for the diagnosis of cervical dysplasia. Am J Pathol. 2003;163(4):1405–1416.
75. P.Guan, R.Howell-Jones, N.Li, et al. Human papillomavirus types in 115,789 HPV-positive women:a meta-analysis from cervical infection to cancer. Int J Cancer. 2012;131(10):2349–2359.
76. S.De Sanjose, W.G.V.Quint, L.Alemany, et al. Human papillomavirus genotype attribution in invasive cervical cancer:a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048–1056.
77. M.J.Khan, P.E.Castle, A.T.Lorincz, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005;97(14):1072–1079.
78. S.K.Kjaer, K.Frederiksen, C.Munk, et al. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection:role of persistence. J Natl Cancer Inst. 2010;102(19):1478–1488.
79. R.M.F.Ebisch, G.M.de Kuyper-de Ridder, R.P.Bosgraaf, et al. The clinical value of HPV genotyping in triage of women with high-risk-HPV-positive self-samples. Int J Cancer. 2016;139:691–699. doi:10.1002/ijc.30090.
80. V.M.J.Verhoef, D.A.M.Heideman, F.J.van Kemenade, et al. Methylation marker analysis and HPV16/18 genotyping in high-risk HPV positive self-sampled specimens to identify women with high grade CIN or cervical cancer. Gynecol Oncol. 2014;135(1):58–63.
81. L.M.A.De Strooper, V.M.J.Verhoef, J.Berkhof, et al. Validation of the FAM19A4/mir124-2 DNA methylation test for both lavage- and brush-based self-samples to detect cervical (pre)cancer in HPV-positive women. Gynecol Oncol. 2016;141:341–347. doi:10.1016/j.ygyno.2016.02.012.
82. M.Cui, N.Chan, M.Liu, et al. Clinical performance of Roche Cobas 4800 HPV test. J Clin Microbiol. 2014;52(6):2210–2211.
83. A.T.Hesselink, J.Berkhof, M.L.van der Salm, et al. Clinical validation of the HPV-risk assay, a novel real-time PCR assay for detection of high-risk human papillomavirus DNA by targeting the E7 region. J Clin Microbiol. 2014;52(3):890–896.
84. M.A.Clarke, N.Wentzensen, L.Mirabello, et al. Human papillomavirus DNA methylation as a potential biomarker for cervical cancer. Cancer Epidemiol Biomarkers Prev. 2012;21(12):2125–2137.• This paper provides a detailed overview on current literature regarding HPV DNA methylation and its biological applications.
85. C.Sun, L.L.Reimers, R.D.Burk. Methylation of HPV16 genome CpG sites is associated with cervix precancer and cancer. Gynecol Oncol. 2011;121(1):59–63.
86. A.T.Lorincz, A.R.Brentnall, D.Scibior-Bentkowska, et al. Validation of a DNA methylation HPV triage classifier in a screening sample. Int J Cancer. 2016;138(11):2745–2751.
87. V.Simanaviciene, V.Popendikyte, Z.Gudleviciene, et al. Different DNA methylation pattern of HPV16, HPV18 and HPV51 genomes in asymptomatic HPV infection as compared to cervical neoplasia. Virology. 2015;484:227–233.
88. L.Mirabello, M.Frimer, A.Harari, et al. HPV16 methyl-haplotypes determined by a novel next-generation sequencing method are associated with cervical precancer. Int J Cancer. 2015;136(4):E146–E153.
89. N.Milutin Gasperov, I.Sabol, P.Planinic, et al. Methylated host cell gene promoters and human papillomavirus type 16 and 18 predicting cervical lesions and cancer. PLoS One. 2015;10(6):e0129452.
90. N.Wentzensen, C.Sun, A.Ghosh, et al. Methylation of HPV18, HPV31, and HPV45 genomes and cervical intraepithelial neoplasia grade 3. J Natl Cancer Inst. 2012;104(22):1738–1749.
91. S.Snellenberg, D.M.Schütze, D.Claassen-Kramer, et al. Methylation status of the E2 binding sites of HPV16 in cervical lesions determined with the Luminex® xMAP™ system. Virology. 2012;422(2):357–365.
92. N.Wentzensen, M.E.Sherman, M.Schiffman, et al. Utility of methylation markers in cervical cancer early detection:appraisal of the state-of-the-science. Gynecol Oncol. 2009;112(2):293–299.•• This paper and Ref. [95] were the first papers to describe that chromosomal aberrations and DNA methylation levels are not only related to severity of disease, but also to duration of lesion presence.
93. I.J.Groves, N.Coleman. Pathogenesis of human papillomavirus-associated mucosal disease. J Pathol. 2015;235(4):527–538.
94. A.Fournier, N.Sasai, M.Nakao, et al. The role of methyl-binding proteins in chromatin organization and epigenome maintenance. Brief Funct Genomics. 2012;11(3):251–264.
95. M.Bierkens, A.T.Hesselink, C.J.L.M.Meijer, et al. CADM1 and MAL promoter methylation levels in hrHPV-positive cervical scrapes increase proportional to degree and duration of underlying cervical disease. Int J Cancer. 2013;133(6):1293–1299.•• This paper and Ref. [92] were the first papers to describe that chromosomal aberrations and DNA methylation levels are not only related to severity of disease, but also to duration of lesion presence.
96. L.M.A.De Strooper, C.J.L.M.Meijer, J.Berkhof, et al. Methylation analysis of the FAM19A4 gene in cervical scrapes is highly efficient in detecting cervical carcinomas and advanced CIN2/3 lesions. Cancer Prev Res (Phila). 2014;7(12):1251–1257.
97. A.Boers, R.P.Bosgraaf, R.W.van Leeuwen, et al. DNA methylation analysis in self-sampled brush material as a triage test in hrHPV-positive women. Br J Cancer. 2014;111(6):1095–1101.
98. R.D.M.Steenbergen, M.Ongenaert, S.Snellenberg, et al. Methylation-specific digital karyotyping of HPV16E6E7-expressing human keratinocytes identifies novel methylation events in cervical carcinogenesis. J Pathol. 2013;231(1):53–62.
99. A.Boers, R.Wang, R.W.van Leeuwen, et al. Discovery of new methylation markers to improve screening for cervical intraepithelial neoplasia grade 2/3. Clin Epigenetics. 2016;8:29.
100. R.Luttmer, L.M.A.De Strooper, M.G.Dijkstra, et al. FAM19A4 methylation analysis in self-samples compared with cervical scrapes for detecting cervical (pre)cancer in HPV-positive women. Br J Cancer. 2016. doi:10.1038/bjc.2016.200
101. L.M.A.De Strooper, M.van Zummeren, R.D.M.Steenbergen, et al. CADM1, MAL and miR124-2 methylation analysis in cervical scrapes to detect cervical and endometrial cancer. J Clin Pathol. 2014;67(12):1067–1071.
102. L.M.A.De Strooper, A.T.Hesselink, J.Berkhof, et al. Combined CADM1/MAL methylation and cytology testing for colposcopy triage of high-risk HPV-positive women. Cancer Epidemiol Biomarkers Prev. 2014;23(9):1933–1937.
103. V.M.J.Verhoef, R.P.Bosgraaf, F.J.van Kemenade, et al. Triage by methylation-marker testing versus cytology in women who test HPV-positive on self-collected cervicovaginal specimens (PROHTECT-3):a randomised controlled non-inferiority trial. Lancet Oncol. 2014;15(3):315–322.•• This study is the first randomized controlled trial that reports on the use of host cell DNA methylation markers as triage tool for HPV-positive self-collected samples.
104. J.J.H.Eijsink, Á.Lendvai, V.Deregowski, et al. A four-gene methylation marker panel as triage test in high-risk human papillomavirus positive patients. Int J Cancer. 2012;130(8):1861–1869.
105. A.Yin, Q.Zhang, X.Kong, et al. JAM3 methylation status as a biomarker for diagnosis of preneoplastic and neoplastic lesions of the cervix. Oncotarget. 2015;6(42):44373–44387.
106. A.Hansel, D.Steinbach, C.Greinke, et al. A promising DNA methylation signature for the triage of high-risk human papillomavirus DNA-positive women. PLoS One. 2014;9(3):e91905.
107. V.M.J.Verhoef, F.J.van Kemenade, L.Rozendaal, et al. Follow-up of high-risk HPV positive women by combined cytology and bi-marker CADM1/MAL methylation analysis on cervical scrapes. Gynecol Oncol. 2015;137(1):55–59.
108. S.Snellenberg, L.M.A.De Strooper, A.T.Hesselink, et al. Development of a multiplex methylation-specific PCR as candidate triage test for women with an HPV-positive cervical scrape. BMC Cancer. 2012;12:551.
109. Q.Tian, Y.Li, F.Wang, et al. MicroRNA detection in cervical exfoliated cells as a triage for human papillomavirus-positive women. J Natl Cancer Inst. 2014;106. doi:10.1093/jnci/dju241.
110. F.-H.Zhao, J.Jeronimo, Y.-L.Qiao, et al. An evaluation of novel, lower-cost molecular screening tests for human papillomavirus in rural China. Cancer Prev Res (Phila). 2013;6(9):938–948.
111. Y.-L.Qiao, J.Jeronimo, F.-H.Zhao, et al. Lower cost strategies for triage of human papillomavirus DNA-positive women. Int J Cancer. 2014;134(12):2891–2901.
112. E.A.Burger, H.Kornør, M.Klemp, et al. HPV mRNA tests for the detection of cervical intraepithelial neoplasia:a systematic review. Gynecol Oncol. 2011;120(3):430–438.
113. D.C.Rijkaart, D.A.M.Heideman, V.M.H.Coupe, et al. High-risk human papillomavirus (hrHPV) E6/E7 mRNA testing by PreTect HPV-proofer for detection of cervical high-grade intraepithelial neoplasia and cancer among hrHPV DNA-positive women with normal cytology. J Clin Microbiol. 2012;50(7):2390–2396.
114. R.Luttmer, J.Berkhof, M.G.Dijkstra, et al. Comparing triage algorithms using HPV DNA genotyping, HPV E7 mRNA detection and cytology in high-risk HPV DNA-positive women. J Clin Virol. 2015;67:59–66.
115. R.P.Bosgraaf, P.J.W.Ketelaars, V.M.J.Verhoef, et al. Reasons for non-attendance to cervical screening and preferences for HPV self-sampling in Dutch women. Prev Med (Baltim). 2014;64:108–113.
116. A.B.Bos, M.Rebolj, J.D.F.Habbema, et al. Nonattendance is still the main limitation for the effectiveness of screening for cervical cancer in the Netherlands. Int J Cancer. 2006;119(10):2372–2375.
117. M.Gök, D.A.M.Heideman, F.J.van Kemenade, et al. HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening:cohort study. BMJ. 2010;340:c1040.
118. M.Arbyn, F.Verdoodt, P.J.F.Snijders, et al. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples:a meta-analysis. Lancet Oncol. 2014;15(2):172–183.
119. M.Arbyn, P.E.Castle. Offering self-sampling kits for HPV testing to reach women who do not attend in the regular cervical cancer screening program. Cancer Epidemiol Biomarkers Prev. 2015;24(5):769–772.